164 related articles for article (PubMed ID: 29968698)
1. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.
Verschelden G; Van Laethem J; Velkeniers B; Ilsen B; Noeparast A; De Grève J
Pol Arch Intern Med; 2018 Jun; 128(6):386-388. PubMed ID: 29968698
[No Abstract] [Full Text] [Related]
2. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
[No Abstract] [Full Text] [Related]
3. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
4. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
6. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.
Ruan GJ; Goyal G; Shah MV; Cohen-Aubart F; Amoura Z; Straetmans N; Benameur N; Haroche J; Go RS;
Pancreas; 2021 Jan; 50(1):e6-e8. PubMed ID: 33370037
[No Abstract] [Full Text] [Related]
7. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.
Roeser A; Cohen-Aubart F; Breillat P; Miyara M; Emile JF; Charlotte F; Donadieu J; Amoura Z; Haroche J
Haematologica; 2019 Nov; 104(11):e502-e505. PubMed ID: 30923093
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.
Pegoraro F; Maniscalco V; Peyronel F; Westenend PJ; Hendriksz TR; Roperto RM; Palumbo AA; Sieni E; Romagnani P; van Bommel EFH; Vaglio A
Blood; 2020 May; 135(22):1994-1997. PubMed ID: 32299103
[No Abstract] [Full Text] [Related]
9. Advances in Understanding and Management of Erdheim-Chester Disease.
Kulkarni AM; Gayam PKR; Aranjani JM
Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
[TBL] [Abstract][Full Text] [Related]
10. Erdheim-Chester disease harboring the BRAF V600E mutation.
Blombery P; Wong SQ; Lade S; Prince HM
J Clin Oncol; 2012 Nov; 30(32):e331-2. PubMed ID: 23008323
[No Abstract] [Full Text] [Related]
11. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
12. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
[TBL] [Abstract][Full Text] [Related]
13. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
[No Abstract] [Full Text] [Related]
14. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
15. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
Wilgenhof S; Neyns B
J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
[No Abstract] [Full Text] [Related]
16. Erdheim-Chester Disease With Cardiovascular Involvement and BRAF V600E Mutation.
Okamura K; Suematsu Y; Morizumi S; Kawata M; Dai Y; Yamakawa M; Ono M
Circ J; 2016 Jun; 80(7):1657-9. PubMed ID: 27296272
[No Abstract] [Full Text] [Related]
17. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
[TBL] [Abstract][Full Text] [Related]
18. B-RAF
Sugaya T; Kanno H; Matsuda M; Handa K; Tateda S; Murakami T; Ozawa H; Itoi E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817643
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.
Amoura A; Haroche J; Emile JF; Barete S; Helias-Rodzewicz Z; Charlotte F; Maisonobe T; Amoura Z; Cohen Aubart F
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e348-e350. PubMed ID: 31002424
[No Abstract] [Full Text] [Related]
20. Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.
Toya T; Ogura M; Toyama K; Yoshimi A; Shinozaki-Ushiku A; Honda A; Honda K; Hosoya N; Murakami Y; Kawashima H; Nannya Y; Arai S; Nakamura F; Shinoda Y; Nangaku M; Miyagawa K; Fukayama M; Moriya-Saito A; Katayama I; Ogura T; Kurokawa M
Haematologica; 2018 Nov; 103(11):1815-1824. PubMed ID: 29976744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
